Taste Assessment of Maxalt Oral Disintegrating Tablets in Children To evaluate the palatability of Maxalt-MLT® ODT in pediatric migraineurs, ages 6 - 11 years.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and Safety of Ertugliflozin Monotherapy in the Treament of Subjects with Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (1) Objective: At Week 26, to assess the effect on HbA1c of 15 mg ertugliflozin as compared with placebo. Hypothesis: At Week 26, the mean reduction from baseline in HbA1c for 15 mg ertugliflozin is...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in subjects 60 years of age and older 1. To determine whether ZOSTAVAX™ administered concomitantly with PNEUMOVAX™ 23 elicits a VZV antibody response that is noninferior to that of ZOSTAVAX™ administered nonconcomitantly. 2. To demonst...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Ensayo aleatorizado, de adaptación y con dos partes de ridaforolimus combinado con dalotuzumab en comparación con exemestano o en comparación con ridaforolimus o dalotuzumab en monoterapia en pacientes con cáncer de mama con receptores estrogénicos positivos";"A Two-Part, Adaptive, Randomized Trial of Ridaforolimus in Combination with Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients En la parte A de este estudio, el objetivo principal es evaluar la eficacia de la combinación de ridaforolimus y dalotuzumab en comparación con exemestano mediante el análisis de la supervivencia sin ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

V212 Lot Consistency Study To determine whether V212 from three consistency lots have similar immunogenicity.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma To determine the duration of PFS in patients with multiple myeloma, after at least 1 prior treatment regimen, treated with bortezomib and vorinostat compared to patients treated with bortezomib and pl...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study of Lenalidomide and Dexamethasone with or without Pembrolizumab in Newly Diagnosed and Treatment-Naïve Multiple Myeloma Compare the Progression Free Survival (PFS) as assessed by independent central review according to the International Myeloma Working Group response criteria, (IMWG criteria) between treatment arms.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Study in Healthy Infants of the Safety, Tolerability, and Immunogenicity of Haemophilus influenzae, Type b/Hepatitis B Vaccine Manufactured With a Modified Process Main objective : (1a) To demonstrate that at 1 month after the third dose of vaccine, both the modified process vaccine and COMVAX™ will induce adequate seroprotection rates (SPR, % of subjects with...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

MK-3475 vs. paclitaxel, Docetaxel or vinflunine in metastatic urothelial cancer -Evaluate PFS per RECIST 1.1 by blinded independent radiologists’ review of all subjects with recurrent/progressive metastatic urothelial cancer treated with pembrolizumab (MK-3475) compared to paclit...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Early Access of MK-0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options This program is designed to provide expanded access to MK-0518 prior to the product’s approval and availability on the market. The safety and tolerability of MK-0518 400 mg b.i.d. for the treatment o...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune